survival data were available (n = 51), median survival of individuals who received adjuvant therapy (11 months [range, 1-108 months]) was similar to survival in those who did not receive adjuvant therapy (10 months [range, 0.5-96.0 months]), despite type of adjuvant received, sex, age at onset, tumor size, interval before metastasis, and local vs distant metastasis.
Discussion. We report 194 cases of mBCC from 1981 through 2011 for a total of 364 cases from 1894 through 2011; the number of mBCC cases seems to be increasing ( Figure) . This increase may simply be publication bias; however, it parallels the well-established climbing incidence of sporadic BCCs. 1 Most cases of mBCC were reported in adult white males, originating from large tumors (7.5 cm) on the head and neck, and spreading to the lymph nodes. In patients who survived less than 1 year after diagnosis, the tumor was significantly larger with an average neglect to seek medical care of 10 years, suggesting the importance of tumor size and delay of treatment in overall prognosis.
Our updated review suggests that the overall prognosis of mBCC continues to be poor, with a median survival of 10 months, despite 44% of patients with mBCC receiving adjuvant chemotherapy or radiation in the past 30 years. These data suggest that radiation and chemotherapy have not significantly improved mBCC survival regardless of age, sex, tumor size, or local vs distant metastasis, although the small sample size may contribute to a lack of power to detect a difference in this rare condition. Our results may be particularly important as historic controls to compare any survival benefit from novel hedgehog pathway inhibitors, such as vismodegib. 4 With the continued development of targeted therapies for BCC, we will likely see changes in the way we manage mBCC that may improve disease-free and overall survival.
Rerecurrence 5 Years After Treatment of Recurrent Cutaneous Basal Cell and Squamous Cell Carcinoma

C
utaneous basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) that have recurred after previous treatment are considered more difficult to cure compared with primary tumors, with overall 5-year re-recurrence rates reported as high as 15.4% 1 for BCC and 5.9% for SCC. 2 Few outcomes data exist from prospective studies, but a randomized controlled study in Europe of facial BCCs found that 5-year recurrence rates after excision or Mohs surgery for 397 primary tumors varied from 2.5% to 4.1%, compared with 2.4% to 12.1% for 202 recurrent tumors. 3 The generalizability of these results to the United States, to other BCCs and SCCs, and after treatments delivered in the community is not clear. We sought to determine the 5-year recurrence rate after treatment of a consecutive cohort of BCCs and SCCs already recurrent at presentation.
Methods. The design of this prospective observational cohort study has been described 4 ; this research was approved by the committee on human research, University of California, San Francisco. All 1536 patients with 1993 BCCs or SCCs in 1999 through 2000 at a universitybased private practice or the dermatology clinics at the affiliated Veterans Affairs Medical Center (VA) were enrolled. We eliminated tumors in patients with basal cell nevus syndrome and restricted the sample to tumors treated with the 3 main therapies: electrodessication and curettage (EDC), elliptical excision, or Mohs surgery. Analysis was limited to patients with follow-up after treatment (93.8%). In this report we compare 126 patients with 137 tumors that were recurrent at presentation with 1174 patients with 1488 primary tumors. Treatment of the primary tumors has been described. 4 Of the recurrent tumors, 13 were treated with EDC, 51 with excision, and 73 with Mohs surgery; 2 recurrent tumors initially treated with excision were retreated with Mohs surgery when tumor was found to be present at the margins of the surgical specimen. Overall, patients with primary tumors were followed for a median of 7.4 years (interquartile range [IQR], 3.0-8.8 years] and recurrent tumors for 7.9 years (IQR, 3.2-8.9 years). Data about recurrence were collected by study staff blinded as much as possible to treatment type. The primary source of data about recurrence was the medical record, supplemented by physical examination by the study dermatologist for patients who consented to participate. Characteristics 5 in the primary and initially recurrent groups were compared using 2 or Fisher exact tests for categorical variables and Mann-Whitney U tests for continuous variables. Unadjusted recurrence rates were calculated using the Kaplan-Meier method. Data were right-censored at the last date of care. Survival functions were compared using the log-rank test.
Results.
At enrollment, patients with recurrent tumors were similar (PϾ.05) to those with primary tumors (mean age, 69.0 years; 76.9% were male). Compared with primary tumors, recurrent tumors were similar in body location and likelihood of being in the H-zone of the face but were more often BCCs (75.6% vs 83.2%; P=.04), were larger (8.0 mm vs 10.0 mm, P=.03), and were more likely to have histopathologic risk factors for recurrence 4 (20.4% vs 29.9%; P=.009). Also, recurrent tumors differed in the 3 treatment groups; for example, those treated with Mohs surgery were more likely to be BCC (P = .04) and located in the H-zone of the face (P Ͻ .001).
Over the follow-up period, 8 recurrent tumors rerecurred (5.8% [95% CI, 1.9%-9.8%]): 3 after excision and 5 after Mohs surgery. No recurrent tumors treated with EDC re-recurred. Details about the 8 recurrent tumors that re-recurred are presented in the Table; 87.5% of tumors that re-recurred were BCCs, and 37.5% were in the H-zone of the face. The median time for detection of recurrence was 1.3 years for recurrent tumors (IQR, 0.97-4.6) and 3.9 years for primary tumors (IQR, 1.8-5.3) (P =.15). Overall, the unadjusted 5-year recurrence 
